Drug Induced Liver Injury Attributed to a Curcumin Supplement

Imam, Zaid; Khasawneh, Majd; Jomaa, Diana; Iftikhar, Hira; SayedAhmad, Ziad

doi:10.1155/2019/6029403

Cited by 15 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety of orally administered curcumin has been clearly demonstrated: the US Food and Drug Administration has approved curcumin as a compound "generally recognized as safe" and also JECFA (The Joint FAO/WHO Expert Committee on Food Additives) and EFSA (European Food Safety Authority) reported the ADI (acceptable daily intake) value of 0-3 mg•kg −1 for curcumin [40]. However, it has to been taken into account that very few reports on the potential adverse effects of curcumin exist: recently, a case report showed a liver injury attributed to a curcumin supplement in a woman with jaundice [41]. Curcumin could also interfere with systemic iron metabolism, suggesting limited application of this compound in patients with chronic disease or anemia [42].…”

Section: Curcumin: Metabolism and Bioavailabilitymentioning

confidence: 99%

Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin

2020

View full text Add to dashboard Cite

Curcumin, a lipophilic polyphenol contained in the rhizome of Curcuma longa (turmeric), has been used for centuries in traditional Asian medicine, and nowadays it is widely used in food as dietary spice worldwide. It has received considerable attention for its pharmacological activities, which appear to act primarily through anti-inflammatory and antioxidant mechanisms. For this reason, it has been proposed as a tool for the management of many diseases, among which are gastrointestinal and neurological diseases, diabetes, and several types of cancer. However, the pharmacology of curcumin remains to be elucidated; indeed, a discrepancy exists between the well-documented in vitro and in vivo activities of curcumin and its poor bioavailability and chemical instability that should limit any therapeutic effect. Recently, it has been hypothesized that curcumin could exert direct regulative effects primarily in the gastrointestinal tract, where high concentrations of this polyphenol have been detected after oral administration. Consequently, it might be hypothesized that curcumin directly exerts its regulatory effects on the gut microbiota, thus explaining the paradox between its low systemic bioavailability and its wide pharmacological activities. It is well known that the microbiota has several important roles in human physiology, and its composition can be influenced by a multitude of environmental and lifestyle factors. Accordingly, any perturbations in gut microbiome profile or dysbiosis can have a key role in human disease progression. Interestingly, curcumin and its metabolites have been shown to influence the microbiota. It is worth noting that from the interaction between curcumin and microbiota two different phenomena arise: the regulation of intestinal microflora by curcumin and the biotransformation of curcumin by gut microbiota, both of them potentially crucial for curcumin activity. This review summarizes the most recent studies on this topic, highlighting the strong connection between curcumin and gut microbiota, with the final aim of adding new insight into the potential mechanisms by which curcumin exerts its effects.

show abstract

Section: Curcumin: Metabolism and Bioavailabilitymentioning

confidence: 99%

Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin

2020

View full text Add to dashboard Cite

show abstract

“…With 11,609 the largest HILI case number was published in 2019 ( Figure 3 ) as a consequence of the ongoing worldwide use of RUCAM for assessing causality in suspected HILI cases ( Table 4 ). In particular, contributing countries were in alphabetical order Australia [ 29 ], Brazil [ 183 ], China [ 48 , 196 , 197 , 198 , 199 , 200 , 201 ], Germany [ 213 , 214 , 215 ], India [ 217 ], Italy [ 222 ], Korea [ 103 ], Spain [ 115 , 117 , 240 , 241 , 242 ], Switzerland [ 244 ], and the US [ 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 ]. Most of the 11,619 HILI cases published in 2019 were from China [ 48 , 196 ] and Korea [ 103 ], with 6971 cases published by Shen et al [ 48 ], 2019 cases reported by Byeon et al [ 103 ], and 1552 cases provided by Chow et al [ 196 ].…”

Section: Worldwide Publications Of Hili Cases Assessed For Causalimentioning

confidence: 99%

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis

Teschke

Danan²

2020

Medicines

View full text Add to dashboard Cite

Background: A large number of idiosyncratic drug induced liver injury (iDILI) and herb induced liver injury(HILI) cases of variable quality has been published but some are a matter of concern if the cases were not evaluated for causality using a robust causality assessment method (CAM) such as RUCAM (Roussel Uclaf Causality Assessment Method) as diagnostiinjuryc algorithm. The purpose of this analysis was to evaluate the worldwide use of RUCAM in iDILI and HILI cases. Methods: The PubMed database (1993–30 June 2020) was searched for articles by using the following key terms: Roussel Uclaf Causality Assessment Method; RUCAM; Idiosyncratic drug induced liver injury; iDILI; Herb induced liver injury; HILI. Results: Considering reports published worldwide since 1993, our analysis showed the use of RUCAM for causality assessment in 95,885 cases of liver injury including 81,856 cases of idiosyncratic DILI and 14,029 cases of HILI. Among the top countries providing RUCAM based DILI cases were, in decreasing order, China, the US, Germany, Korea, and Italy, with China, Korea, Germany, India, and the US as the top countries for HILI. Conclusion: Since 1993 RUCAM is certainly the most widely used method to assess causality in IDILI and HILI. This should encourage practitioner, experts, and regulatory agencies to use it in order to reinforce their diagnosis and to take sound decisions.

show abstract

“…Additionally, the recurrence of liver malfunction was more likely after a second re-exposure. Incidentally, Iman et al described a case of curcumin-induced hepatocellular damage in a 78 year old woman admitted with jaundice, with a latency time of one month [78]. Laboratory investigations failed to find any other cause of acute hepatitis.…”

Section: Side Effects Of Curcuminmentioning

confidence: 99%

Curcumin and Colorectal Cancer: From Basic to Clinical Evidences

Pricci

Girardi

Giorgio

et al. 2020

IJMS

151

100

View full text Add to dashboard Cite

Curcumin diffuses through cell membranes into the endoplasmic reticulum, mitochondria, and nucleus, where it exerts actions, as an antioxidant property. Therefore, its use has been advocated for chemopreventive, antimetastatic, and anti-angiogenic purposes. We conducted a literature review to summarize studies investigating the relationship between curcumin and colorectal cancer (CRC). In vitro studies, performed on human colon cancer cell lines, showed that curcumin inhibited cellular growth through cycle arrest at the G2/M and G1 phases, as well as stimulated apoptosis by interacting with multiple molecular targets. In vivo studies have been performed in inflammatory and genetic CRC animal models with a chemopreventive effect. To improve curcumin bioavailability, it has been associated with small particles that increase its absorption when orally administered with excellent results on both inflammation and carcinogenesis. Curcumin has been used, moreover, as a component of dietetic formulations for CRC chemoprevention. These combinations showed in vitro and in vivo anticarcinogenetic properties in inflammation-related and genetic CRC. A synergic effect was suggested using an individual constituent dosage, which was lower than that experimentally used “in vivo” for single components. In conclusion, curcumin falls within the category of plant origin substances able to prevent CRC in animals. This property offers promising expectations in humans.

show abstract

Drug Induced Liver Injury Attributed to a Curcumin Supplement

Cited by 15 publications

References 13 publications

Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin

Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin

Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis

Curcumin and Colorectal Cancer: From Basic to Clinical Evidences

Contact Info

Product

Resources

About